A Phase 2 interventional study of Daunorubicin and Cytarabine in Acute Leukaemia, sponsored by Novartis Pharmaceuticals. Completed at 42 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Leukemia by Novartis — 1 open to participants now, 3 under way, 1 of them phase 3. Leukemia · Novartis.
Among the 35 studies in Leukemia by Novartis, this one is the 10th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2013, is one of 14 in phase 2, and was the 24th registered.
2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.
Browse Leukemia studies →1 of the 35 studies in Leukemia by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
By country, each count listing its studies:
Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 9 · Phase 4 4
First in 2000; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 40 across 1,770 interventional studies indexed under Leukemia.
Median enrollment 105 across the 28 interventional studies. Of the 30 that completed or were terminated, 22 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Leukemia by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized, blinded, placebo-controlled study was to provide clinical safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute Myeloid Leukemia (AML) receiving standard induction chemotherapy with daunorubicin plus cytarabine. A minimum of 120 evaluable subjects newly diagnosed with AML was stratified by antecedent malignant hematologic disorder and age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Total \<=1.5 x (ULN) except for Gilbert's syndrome, or other conditions that are not indicative of inadequate liver function (i.e. elevation of indirect bilirubin (haemolytic) in the absence of [ALT] abnormality).
ALT \<=3 x ULN. Serum Creatinine \<=2.5 x ULN.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received induction chemotherapy consisting of daunorubicin bolus intravenous (IV) infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by Eltrombopag once daily orally starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the dose was increased until a platelet count of at least 200 Gi/L was achieved/until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
Drug: Daunorubicin · Drug: Cytarabine · Drug: Eltrombopag
Subject received induction chemotherapy consisting of daunorubicin bolus IV infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by matching placebo once daily oral dose starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the matching placebo was given until a platelet count of at least 200 Gi/L was achieved/ until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received a second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
Drug: Daunorubicin · Drug: Cytarabine · Drug: Placebo
For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects \> 60 years: daunorubicin dose was adjusted to 60mg /m2.
100 mg/m2/day continuous IV infusion on Days 1 through 7.
200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were \<100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were \<100 Gi/L.
Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were \<100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were \<100 Gi/L.
Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability.
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function.
Time frame: From the time the first dose of study treatment was administered until 30 days following discontinuation of investigational product regardless of initiation of a new cancer therapy or transfer to hospice
Change From Baseline in the Left Ventricular Ejection Fraction (LVEF).
LVEF is a measurement of the percentage of blood leaving heart each time it contracts. LVEF was assessed by an echocardiogram (ECHO) or Multiple Gated Acquisition scan (MUGA). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as the Day 42 value minus the Baseline value.
Time frame: Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Number of Participants With Worst-case Grade Changes From Baseline in the Hematology Parameters
The number of participants with a maximum post-baseline grade increase of Grade 3 (G3) or Grade 4 (G4) from their baseline grade are presented. Hematology parameters included only lab tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Time frame: Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Number of Participants With Worst-case Grade Changes From Baseline in the Clinical Chemistry Parameters
The number of participants with a maximum post-baseline grade increase of Grade 3 or Grade 4 from their baseline grade are presented. Clinical Clinical Chemistry parameters included only lab tests that are gradable by CTCAE v4.0.
Time frame: Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Number of Participants With Liver Events.
The number of participants with liver enzyme (ALT, AST, ALP, Total bilirubin) abnormalities while receiving study treatment in each arm are presented.
Time frame: 8 weeks
Number of Participants With Worst-case Changes From Baseline in Electrocardiogram (ECG) Values
The number of participants with worst case post-baseline changes (normal, abnormal - not clinically significant \[NCS\], abnormal - clinically significant \[NS\]) in ECG QT prolonged values are presented. The protocol does not define the criteria for normal, abnormal-NCS and abnormal CS ECG. The outcome was based solely on the investigator interpretation of ECG tracings.
Time frame: Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Number of Participants With Worst-case Changes From Baseline in the Eastern Cooperative Oncology Group (ECOG) Performance Status
The number of participants with worst case post-baseline changes (improved, no change, deteriorated) are presented.
Time frame: Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Worst-case Change From Baseline in Pulse Rate Values
The worst-case post Baseline high and low changes in pulse rate values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Post Baseline is defined as the highest and lowest non-missing post Baseline value respectively. Change from Baseline was calculated as the post Baseline value minus the Baseline value.
Time frame: Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Worst-case Post Baseline Change in Blood Pressure Values From Baseline
The worst-case post Baseline high changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as the visit value minus the Baseline value.
Time frame: Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Worst-case Post Baseline Change in Temperature Values From Baseline
The worst-case post Baseline high and low changes in temperature values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Post Baseline was defined as the highest and lowest non-missing post Baseline value respectively. Change from Baseline was calculated as the post Baseline value minus the Baseline value.
Time frame: Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Plasma Pharmacokinetics (PK) Parameter of Daunorubicin: Half-life (t1/2)
Daunorubicin half-life. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Plasma Pharmacokinetics (PK) Parameter of Daunorubicinol: Half-life (t1/2)
Daunorubicinol half-life. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Daunorubicin Dose-normalized Plasma: AUC(0-∞)
Daunorubicin AUC(0-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Daunorubicinol Dose-normalized Plasma: AUC(0-∞)
Daunorubicinol AUC(0-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Daunorubicin Dose-normalized Plasma: AUC(24-∞)
Daunorubicin AUC(24-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Daunorubicinol Dose-normalized Plasma: AUC(24-∞)
Daunorubicinol AUC(24-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Daunorubicin Dose-normalized Plasma: AUC(0-t)
Daunorubicin AUC(0-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Daunorubicinol Dose-normalized Plasma: AUC(0-t)
daunorubicinol AUC(0-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Daunorubicin Dose-normalized Plasma: AUC(24-t)
Daunorubicin AUC(24-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Daunorubicinol Dose-normalized Plasma: AUC(24-t)
Daunorubicinol AUC(24-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Daunorubicin Dose-normalized Plasma: Cmax
Daunorubicin Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Daunorubicinol Dose-normalized Plasma: Cmax
Daunorubicinol Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Cycle 2: Daunorubicin Dose-normalized Plasma: AUC(0-24)
Cycle 2 Daunorubicin AUC(0-24). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Cycle 2: Daunorubicinol Dose-normalized Plasma: AUC(0-24)
Cycle 2 Daunorubicinol AUC(0-24). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Cycle 2: Daunorubicin Dose-normalized Plasma: Cmax
Cycle 2 Daunorubicin Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Cycle 2: Daunorubicinol Dose-normalized Plasma: Cmax
Cycle 2 Daunorubicinol Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Time frame: Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Number of Platelet Transfusions Per Week Within Cycles
This was the average number of platelet transfusions per week within cycles.
Time frame: Post-Base line up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Time to Platelet Count Recovery >=20 Gi/L
Time to Platelet counts \>= 20 Gi/L for 3 consecutive days, unaided by transfusions in patients with \< 20 Gi/L after chemotherapy. For this endpoint, the event required platelet count to be \>= 20 Gi/L for 3 consecutive days. Hematology was assessed daily during hospital stay but only weekly after hospital discharge and thus, platelet count was not always available for 3 consecutive days to confirm the achievement of platelet count recovery.
Time frame: From last dose of chemotherapy to up to end of study year 2 assessment
Time to Platelet Recovery >=100 Gi/L
Time to platelet counts \>= 100 Gi/L unaided by transfusions in participants with \< 100 Gi/L after chemotherapy.
Time frame: From last dose of chemotherapy to up to end of study year 2 assessment
Number of Participants Who Achieved Platelet Count Recovery by Day 21
Number of participants with platelet counts 20 Gi/L for 3 consecutive days, unaided by transfusions, in patients with \< 20 Gi/L after chemotherapy.
Time frame: By Day 21
Summary of Platelet Counts Over Time
Platelet counts over time
Time frame: Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit
Maximum Duration (Days) of Platelet Transfusion Independence
Maximum time period (in days) during which the patient did not receive any platelet transfusion
Time frame: At differnt time points from start of treatment and up to end of study year 2 assessment
Percentage of Patients Who Achieved Platelet Transfusion Independence ≥ 28 Days
Percentage of patients who achieved platelet transfusion independence ≥ 28 days.
Time frame: From start of treatment and up to end of study year 2 assessment
Time to Neutrophil Engraftment
Time to absolute neutrophil count (ANC) \>= 0.5 Gi/L for 3 consecutive days in participants with ANC \< 0.5 Gi/L after chemotherapy
Time frame: At different time points from last dose of chemotherapy up to end of study year 2 assessment
Summary of Absolute Neutrophil Counts (ANC)
Absolute neutrophil counts over time
Time frame: Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit
Summary of Hemoglobin
Hemoglobin level over time
Time frame: Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit
Incidence of Hemorrhagic Events
Incidence of bleeding events using WHO bleeding grade (G0=No bleeding, G1=Petechiae, G2=Mild blood loss, G3=Gross blood loss, G4=Debilitating blood loss) by week and cycle
Time frame: Baseline, weekly within induction and re-induction cycles, end of therapy
Percentage of Participants With Disease Response Rate and Type of Response
Disease response as assessed by the investigator using the AML International Working Group Response Assessment at the end of therapy/remission assessment visit; Complete remission (CR): defined as transfusion independence, blood count recovery (Abs. neutrophil count \> 1.0 Gi/L and Platelet count \> 100.0 Gi/L), no leukemic blast in peripheral blood, Bone Marrow (BM) blasts \< 5%, maturation of all cell lines, Auer rods not detectable, and no extramedullary disease. Partial remission (PR): defined as CR except that for BM blasts where a decrease of at least 50% of BM blasts to 5-25% in BM aspirate is sufficient or BM blasts \< 5% with Auer rods present. Overall response (OR) = CR + PR.
Time frame: Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Overall Survival (OS)
Overall survival defined as the time form randomization until the date of death due to any cause.
Time frame: From randomization to end of 2-year follow-up
Number of Participants Who Required Medical Resource Utilization
Medical Resource Utilization pertained to unscheduled hospitalizations, unscheduled office visits, unscheduled laboratory tests, and unscheduled procedures.
Time frame: At screening and from start of treatment to end of therapy/remission assessment visit (Day 42 of the latest chemotherapy cycle)
Participants (Par.) diagnosed with Acute Myelogenous Leukemia (AML) of any subtype (except acute promyelocytic \[M3\] or acute megakaryocytic leukaemia \[M7\]) were eligible for the study.
| Milestone | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Started | 74 | 74 |
| Completed | 22 | 33 |
| Not completed | 52 | 41 |
| Withdrew: Death | 39 | 30 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 4 | 1 |
| Withdrew: Physician decision | 3 | 2 |
| Withdrew: Withdrawal by subject | 5 | 8 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function.
| Participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Any AE | 72 | 66 |
| Any SAE | 24 | 14 |
LVEF is a measurement of the percentage of blood leaving heart each time it contracts. LVEF was assessed by an echocardiogram (ECHO) or Multiple Gated Acquisition scan (MUGA). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as the Day 42 value minus the Baseline value.
| LVEF percent | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| chnge from baseline (BL) to end of study | -2.5 ± 7.81 | -4.3 ± 8.54 |
| change from BL to worse post-BL case | -4.1 ± 8.61 | -5.7 ± 9.05 |
The number of participants with a maximum post-baseline grade increase of Grade 3 (G3) or Grade 4 (G4) from their baseline grade are presented. Hematology parameters included only lab tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
| Participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Hemoglobin Low, G3 | 53 | 46 |
| Leukocytes, G3 | 10 | 10 |
| Leukocytes, G4 | 9 | 5 |
| Lymphocytes Low, G3 | 31 | 26 |
| Lymphocytes Low, G4 | 35 | 38 |
| Neutrophils, G4 | 44 | 39 |
| Platelets, G3 | 1 | 0 |
| Platelets, G4 | 63 | 56 |
The number of participants with a maximum post-baseline grade increase of Grade 3 or Grade 4 from their baseline grade are presented. Clinical Clinical Chemistry parameters included only lab tests that are gradable by CTCAE v4.0.
| Participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Alanine Aminotransferase, G3 | 1 | 5 |
| Albumin, G3 | 6 | 4 |
| Aspartate Aminotransferase, G3 | 0 | 1 |
| Bilirubin, G3 | 1 | 4 |
| Bilirubin, G4 | 0 | 1 |
| Calcium Low, G3 | 0 | 1 |
| Creatinine, G3 | 0 | 1 |
| Creatinine, G4 | 1 | 0 |
| Glucose High, G3 | 6 | 3 |
| Glucose High, G4 | 0 | 1 |
| Magnesium Low, G3 | 0 | 1 |
| Magnesium High, G3 | 3 | 0 |
| Phosphate, G3 | 10 | 19 |
| Phosphate, G4 | 1 | 0 |
| Potassium Low, G3 | 8 | 10 |
| Potassium Low, G4 | 0 | 2 |
| Potassium High, G3 | 4 | 0 |
| Potassium High, G4 | 1 | 1 |
| Sodium Low, G3 | 3 | 4 |
| Urate, G4 | 3 | 0 |
The number of participants with liver enzyme (ALT, AST, ALP, Total bilirubin) abnormalities while receiving study treatment in each arm are presented.
| Participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Number of Participants With Liver Events. | 2 | 6 |
The number of participants with worst case post-baseline changes (normal, abnormal - not clinically significant \[NCS\], abnormal - clinically significant \[NS\]) in ECG QT prolonged values are presented. The protocol does not define the criteria for normal, abnormal-NCS and abnormal CS ECG. The outcome was based solely on the investigator interpretation of ECG tracings.
| Participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Normal | 34 | 33 |
| Abnormal - NCS | 23 | 29 |
| Abnormal - CS | 2 | 1 |
The number of participants with worst case post-baseline changes (improved, no change, deteriorated) are presented.
| Participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Deteriorated | 36 | 36 |
| Improved | 0 | 1 |
| No Change | 37 | 34 |
The worst-case post Baseline high and low changes in pulse rate values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Post Baseline is defined as the highest and lowest non-missing post Baseline value respectively. Change from Baseline was calculated as the post Baseline value minus the Baseline value.
| Beats/minute | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| High | 18.48 ± 20.616 | 17.73 ± 15.112 |
| Low | -10.36 ± 14.039 | -11.24 ± 12.123 |
The worst-case post Baseline high changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as the visit value minus the Baseline value.
| millimeter of mercury (mmHg) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| SBP | 14.59 ± 17.936 | 14.34 ± 14.626 |
| DBP | 9.38 ± 12.000 | 12.61 ± 10.947 |
The worst-case post Baseline high and low changes in temperature values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Post Baseline was defined as the highest and lowest non-missing post Baseline value respectively. Change from Baseline was calculated as the post Baseline value minus the Baseline value.
| Degrees Celsius | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| High | 0.62 ± 0.941 | 0.77 ± 0.879 |
| Low | -0.44 ± 0.628 | -0.63 ± 0.592 |
Daunorubicin half-life. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| hour (h) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Plasma Pharmacokinetics (PK) Parameter of Daunorubicin: Half-life (t1/2) | 15.754 (13.969 to 17.766) | 13.709 (12.103 to 15.527) |
Daunorubicinol half-life. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| hour (h) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Plasma Pharmacokinetics (PK) Parameter of Daunorubicinol: Half-life (t1/2) | 22.735 (21.187 to 24.396) | 21.603 (20.232 to 23.067) |
Daunorubicin AUC(0-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (h*ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Daunorubicin Dose-normalized Plasma: AUC(0-∞) | 8.0807 (7.0672 to 9.2396) | 8.7880 (7.3893 to 10.451) |
Daunorubicinol AUC(0-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (h*ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Daunorubicinol Dose-normalized Plasma: AUC(0-∞) | 63.997 (58.686 to 69.746) | 62.835 (58.673 to 67.292) |
Daunorubicin AUC(24-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (h*ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Daunorubicin Dose-normalized Plasma: AUC(24-∞) | 0.87496 (0.76202 to 1.0046) | 0.72315 (0.62633 to 0.83493) |
Daunorubicinol AUC(24-∞). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (h*ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Daunorubicinol Dose-normalized Plasma: AUC(24-∞) | 24.537 (22.052 to 27.301) | 23.039 (21.169 to 25.074) |
Daunorubicin AUC(0-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (h*ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Daunorubicin Dose-normalized Plasma: AUC(0-t) | 7.9523 (6.9485 to 9.1012) | 8.6723 (7.2855 to 10.323) |
daunorubicinol AUC(0-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (h*ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Daunorubicinol Dose-normalized Plasma: AUC(0-t) | 62.463 (57.268 to 68.129) | 61.608 (57.500 to 66.009) |
Daunorubicin AUC(24-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (h*ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Daunorubicin Dose-normalized Plasma: AUC(24-t) | 0.76524 (0.65947 to 0.88797) | 0.59660 (0.48882 to 0.72813) |
Daunorubicinol AUC(24-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (h*ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Daunorubicinol Dose-normalized Plasma: AUC(24-t) | 22.963 (20.557 to 25.651) | 21.821 (20.020 to 23.783) |
Daunorubicin Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Daunorubicin Dose-normalized Plasma: Cmax | 5.1527 (3.9561 to 6.7114) | 6.4113 (4.6773 to 8.7882) |
Daunorubicinol Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Daunorubicinol Dose-normalized Plasma: Cmax | 3.5770 (3.0433 to 4.2044) | 3.3640 (2.8433 to 3.9799) |
Cycle 2 Daunorubicin AUC(0-24). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (h*ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Cycle 2: Daunorubicin Dose-normalized Plasma: AUC(0-24) | 10.315 (6.7932 to 15.662) | 8.1146 (6.0221 to 10.934) |
Cycle 2 Daunorubicinol AUC(0-24). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (h*ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Cycle 2: Daunorubicinol Dose-normalized Plasma: AUC(0-24) | 34.067 (26.479 to 43.829) | 30.820 (24.148 to 39.335) |
Cycle 2 Daunorubicin Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Cycle 2: Daunorubicin Dose-normalized Plasma: Cmax | 11.141 (4.3653 to 28.432) | 3.8905 (1.2805 to 11.820) |
Cycle 2 Daunorubicinol Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
| (ug/ml)/(mg/m2) | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Cycle 2: Daunorubicinol Dose-normalized Plasma: Cmax | 4.0200 (2.5302 to 6.3870) | 1.9868 (1.4247 to 2.7708) |
This was the average number of platelet transfusions per week within cycles.
| Platelet transfusions per week | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Number of Platelet Transfusions Per Week Within Cycles | 1.5 ± 1.18 | 1.4 ± 1.22 |
Time to Platelet counts \>= 20 Gi/L for 3 consecutive days, unaided by transfusions in patients with \< 20 Gi/L after chemotherapy. For this endpoint, the event required platelet count to be \>= 20 Gi/L for 3 consecutive days. Hematology was assessed daily during hospital stay but only weekly after hospital discharge and thus, platelet count was not always available for 3 consecutive days to confirm the achievement of platelet count recovery.
| Months | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Time to Platelet Count Recovery >=20 Gi/L | NA (NA to NA) | NA (NA to NA) |
Time to platelet counts \>= 100 Gi/L unaided by transfusions in participants with \< 100 Gi/L after chemotherapy.
| Months | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Time to Platelet Recovery >=100 Gi/L | 0.69 (0.69 to 0.76) | 0.69 (0.69 to 0.82) |
Number of participants with platelet counts 20 Gi/L for 3 consecutive days, unaided by transfusions, in patients with \< 20 Gi/L after chemotherapy.
| Count of participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Number of Participants Who Achieved Platelet Count Recovery by Day 21 | 4 | 7 |
Platelet counts over time
| Gi/L | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Baseline | 51.5 (5 to 241) | 50.0 (9 to 232) |
| C1D1 | 52.0 (5 to 241) | 48.5 (9 to 232) |
| C1D2 | 43.5 (4 to 237) | 42.0 (5 to 368) |
| C1D3 | 35.5 (4 to 226) | 37.0 (7 to 220) |
| C1D4 | 36.5 (3 to 227) | 29.0 (5 to 146) |
| C1D5 | 33.0 (3 to 201) | 29.0 (5 to 146) |
| C1D6 | 32.0 (4 to 164) | 30.0 (6 to 125) |
| C1D7 | 27.0 (3 to 123) | 27.0 (4 to 102) |
| C1D8 | 24.0 (2 to 99) | 22.0 (4 to 80) |
| C1D9 | 20.5 (1 to 109) | 19.0 (5 to 59) |
| C1D14 | 16.5 (0 to 70) | 18.0 (1 to 81) |
| C1D21 | 39.0 (5 to 325) | 25.0 (2 to 232) |
| C1D28 | 484.5 (14 to 1590) | 121.0 (7 to 539) |
| C1D35 | 547.0 (15 to 1493) | 181.0 (10 to 424) |
| C1D42 | — | 304.0 (304 to 304) |
| C2D1 | 31.0 (12 to 1059) | 30.5 (10 to 432) |
| C2D2 | 26.0 (3 to 831) | 28.5 (8 to 400) |
| C2D3 | 25.5 (0 to 730) | 29.0 (8 to 437) |
| C2D4 | 32.0 (2 to 678) | 35.5 (11 to 454) |
| C2D5 | 37.0 (9 to 516) | 22.0 (12 to 476) |
| C2D6 | 27.0 (4 to 430) | 33.0 (7 to 533) |
| C2D7 | 24.0 (6 to 295) | 28.5 (12 to 390) |
| C2D14 | 10.5 (3 to 31) | 16.0 (6 to 66) |
| C2D21 | 27.0 (9 to 86) | 38.0 (8 to 141) |
| C2D28 | 68.0 (48 to 333) | 173.0 (32 to 479) |
| C2D35 | 515.0 (412 to 618) | 272.0 (26 to 329) |
| C2D42 | — | 147.5 (45 to 250) |
Maximum time period (in days) during which the patient did not receive any platelet transfusion
| Days | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Maximum Duration (Days) of Platelet Transfusion Independence | 29.0 (2 to 57) | 29.5 (2 to 77) |
Percentage of patients who achieved platelet transfusion independence ≥ 28 days.
| Percentage of participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Percentage of Patients Who Achieved Platelet Transfusion Independence ≥ 28 Days | 55 | 53 |
Time to absolute neutrophil count (ANC) \>= 0.5 Gi/L for 3 consecutive days in participants with ANC \< 0.5 Gi/L after chemotherapy
| Months | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Time to Neutrophil Engraftment | NA (NA to NA) | NA (NA to NA) |
Absolute neutrophil counts over time
| Gi/L | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Baseline | 0.8 (0 to 37) | 0.5 (0 to 50) |
| C1D1 | 0.8 (0 to 37) | 0.6 (0 to 50) |
| C1D2 | 0.6 (0 to 41) | 0.5 (0 to 41) |
| C1D3 | 0.6 (0 to 59) | 0.4 (0 to 26) |
| C1D4 | 0.4 (0 to 35) | 0.2 (0 to 17) |
| C1D5 | 0.3 (0 to 21) | 0.2 (0 to 2) |
| C1D6 | 0.2 (0 to 35) | 0.1 (0 to 1) |
| C1D7 | 0.1 (0 to 29) | 0.1 (0 to 1) |
| C1D8 | 0.1 (0 to 21) | 0.0 (0 to 1) |
| C1D9 | 0.0 (0 to 7) | 0.0 (0 to 1) |
| C1D14 | 0.0 (0 to 1) | 0.0 (0 to 0) |
| C1D21 | 0.6 (0 to 18) | 0.3 (0 to 7) |
| C1D28 | 4.3 (0 to 47) | 2.7 (0 to 25) |
| C1D35 | 2.2 (0 to 56) | 1.7 (0 to 12) |
| C1D42 | — | 3.1 (3.1 to 3.1) |
| C2D1 | 0.1 (0 to 7) | 0.0 (0 to 5) |
| C2D2 | 0.1 (0 to 3) | 0.2 (0 to 4) |
| C2D3 | 0.2 (0 to 5) | 0.5 (0 to 4) |
| C2D4 | 0.3 (0 to 3) | 0.5 (0 to 2) |
| C2D5 | 0.2 (0 to 2) | 0.1 (0 to 3) |
| C2D6 | 0.1 (0 to 1) | 0.1 (0 to 3) |
| C2D7 | 0.0 (0 to 1) | 0.1 (0 to 2) |
| C2D14 | 0.0 (0 to 0) | 0.0 (0 to 0) |
Hemoglobin level over time
| g/L | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Baseline | 87.6 (63 to 123) | 87.0 (67 to 121) |
| C1D1 | 88.0 (67 to 123) | 86.0 (67 to 121) |
| C1D2 | 88.0 (58 to 124) | 83.0 (62 to 130) |
| C1D3 | 86.0 (52 to 108) | 82.0 (59 to 130) |
| C1D4 | 83.0 (60 to 105) | 81.5 (46 to 120) |
| C1D5 | 84.0 (60 to 114) | 83.0 (50 to 126) |
| C1D6 | 86.0 (67 to 118) | 82.0 (52 to 119) |
| C1D7 | 85.0 (58 to 116) | 83.0 (57 to 110) |
| C1D8 | 85.3 (65 to 118) | 84.0 (57 to 108) |
| C1D9 | 84.5 (64 to 114) | 81.5 (62 to 109) |
| C1D14 | 85.0 (60 to 123) | 84.0 (59 to 109) |
| C1D21 | 88.0 (77 to 117) | 88.0 (72 to 116) |
| C1D28 | 99.0 (78 to 138) | 98.0 (79 to 125) |
| C1D35 | 99.0 (81 to 131) | 94.0 (74 to 130) |
| C1D42 | — | 98.0 (98 to 98) |
| C2D1 | 94.5 (76 to 124) | 82.5 (72 to 111) |
| C2D2 | 88.5 (72 to 112) | 86.5 (69 to 104) |
| C2D3 | 86.5 (65 to 110) | 80.0 (68 to 97) |
| C2D4 | 89.0 (72 to 106) | 86.5 (74 to 109) |
| C2D5 | 88.0 (67 to 101) | 84.0 (72 to 93) |
| C2D6 | 84.0 (68 to 102) | 85.0 (70 to 96) |
| C2D7 | 84.5 (66 to 99) | 83.0 (57 to 97) |
| C2D14 | 77.5 (66 to 101) | 87.0 (79 to 96) |
| C2D21 | 86.0 (43 to 99) | 91.0 (74 to 110) |
| C2D28 | 89.0 (80 to 92) | 80.0 (72 to 114) |
| C2D35 | 104.0 (101 to 107) | 87.0 (85 to 119) |
| C2D42 | — | 90.5 (86 to 95) |
Incidence of bleeding events using WHO bleeding grade (G0=No bleeding, G1=Petechiae, G2=Mild blood loss, G3=Gross blood loss, G4=Debilitating blood loss) by week and cycle
| Participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| C1D7 - GRADE 0 | 58 | 47 |
| C1D7 - GRADE 1 | 9 | 16 |
| C1D7 - GRADE 2 | 5 | 6 |
| C1D7 - GRADE 3 | 1 | 0 |
| C1D14 - GRADE 0 | 42 | 43 |
| C1D14 - GRADE 1 | 16 | 13 |
| C1D14 - GRADE 2 | 5 | 6 |
| C1D14 - GRADE 3 | 1 | 0 |
| C1D21 - GRADE 0 | 36 | 43 |
| C1D21 - GRADE 1 | 13 | 7 |
| C1D21 - GRADE 2 | 3 | 1 |
| C1D21 - GRADE 3 | 0 | 1 |
| C1D28 - GRADE 0 | 31 | 25 |
| C1D28 - GRADE 1 | 4 | 3 |
| C1D28 - GRADE 2 | 2 | 0 |
| C1D28 - GRADE 3 | 0 | 0 |
| C1D35 - GRADE 0 | 12 | 11 |
| C1D35 - GRADE 1 | 2 | 2 |
| C1D35 - GRADE 2 | 0 | 0 |
| C1D35 - GRADE 3 | 0 | 0 |
| C1D42 - GRADE 0 | — | 0 |
| C1D42 - GRADE 1 | — | 1 |
| C1D42 - GRADE 2 | — | 0 |
| C1D42 - GRADE 3 | — | 0 |
| C2D1 - GRADE 0 | 8 | 8 |
| C2D1 - GRADE 1 | 1 | 4 |
| C2D1 - GRADE 2 | 1 | 0 |
| C2D1 - GRADE 3 | 0 | 0 |
| C2D7 - GRADE 0 | 9 | 8 |
| C2D7 - GRADE 1 | 0 | 3 |
| C2D7 - GRADE 2 | 1 | 0 |
| C2D7 - GRADE 3 | 0 | 0 |
| C2D14 - GRADE 0 | 8 | 7 |
| C2D14 - GRADE 1 | 0 | 3 |
| C2D14 - GRADE 2 | 0 | 0 |
| C2D14 - GRADE 3 | 0 | 0 |
| C2D21 - GRADE 0 | 7 | 7 |
| C2D21 - GRADE 1 | 1 | 2 |
| C2D21 - GRADE 2 | 0 | 0 |
| C2D21 - GRADE 3 | 0 | 0 |
| C2D28 - GRADE 0 | 5 | 7 |
| C2D28 - GRADE 1 | 0 | 1 |
| C2D28 - GRADE 2 | 0 | 0 |
| C2D28 - GRADE 3 | 0 | 0 |
| C2D35 - GRADE 0 | 3 | 2 |
| C2D35 - GRADE 1 | 0 | 1 |
| C2D35 - GRADE 2 | 0 | 0 |
| C2D35 - GRADE 3 | 0 | 0 |
| C2D42 - GRADE 0 | — | 0 |
| C2D42 - GRADE 1 | — | 1 |
| C2D42 - GRADE 2 | — | 0 |
| C2D42 - GRADE 3 | — | 0 |
| Remission visit GRADE 0 | 56 | 58 |
| Remission visit GRADE 1 | 2 | 4 |
| Remission visit GRADE 2 | 3 | 0 |
| Remission visit GRADE 3 | 1 | 0 |
Disease response as assessed by the investigator using the AML International Working Group Response Assessment at the end of therapy/remission assessment visit; Complete remission (CR): defined as transfusion independence, blood count recovery (Abs. neutrophil count \> 1.0 Gi/L and Platelet count \> 100.0 Gi/L), no leukemic blast in peripheral blood, Bone Marrow (BM) blasts \< 5%, maturation of all cell lines, Auer rods not detectable, and no extramedullary disease. Partial remission (PR): defined as CR except that for BM blasts where a decrease of at least 50% of BM blasts to 5-25% in BM aspirate is sufficient or BM blasts \< 5% with Auer rods present. Overall response (OR) = CR + PR.
| Percentage of participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Overall response | 70 | 73 |
| Complete Remission (CR) | 65 | 70 |
| Partial Remission (PR) | 5 | 3 |
Overall survival defined as the time form randomization until the date of death due to any cause.
| Count of participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Overall Survival (OS) | 39 | 30 |
Medical Resource Utilization pertained to unscheduled hospitalizations, unscheduled office visits, unscheduled laboratory tests, and unscheduled procedures.
| Count of participants | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| In-patient hospitalizations/ admissions? | 3 | 4 |
| Diagnostic imaging procedures performed? | 3 | 4 |
| Health care resources use or emergency visits? | 8 | 6 |
| Out-patient lab tests performed? | 6 | 6 |
Collected over Adverse events and serious adverse events were collected from Day 1 of cycle 1 until last dose of investigational product + 30 days i.e. a maximum of 114 days (42 days for the induction cycle + 42 days for the re-induction cycle + 30 days for the follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag (ELQ) QD | 11/74 (14.9%) | 24/74 (32.4%) | 71/74 (95.9%) |
| Placebo QD | 4/71 (5.6%) | 14/71 (19.7%) | 66/71 (93%) |
| Event | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 3/74 | 1/71 |
| SepsisInfections and infestations | 1/74 | 2/71 |
| Septic shockInfections and infestations | 2/74 | 2/71 |
| Ejection fraction decreasedInvestigations | 0/74 | 2/71 |
| Atrial fibrillationCardiac disorders | 2/74 | 0/71 |
| Haemorrhage intracranialNervous system disorders | 2/74 | 0/71 |
| Cardiac failureCardiac disorders | 1/74 | 1/71 |
| Cardiac failure congestiveCardiac disorders | 0/74 | 1/71 |
| CardiomyopathyCardiac disorders | 0/74 | 1/71 |
| ConstipationGastrointestinal disorders | 0/74 | 1/71 |
| Event | Eltrombopag (ELQ) QD | Placebo QD |
|---|---|---|
| NauseaGastrointestinal disorders | 37/74 | 46/71 |
| DiarrhoeaGastrointestinal disorders | 42/74 | 43/71 |
| Febrile neutropeniaBlood and lymphatic system disorders | 38/74 | 42/71 |
| VomitingGastrointestinal disorders | 27/74 | 27/71 |
| Decreased appetiteMetabolism and nutrition disorders | 22/74 | 27/71 |
| HypokalaemiaMetabolism and nutrition disorders | 20/74 | 27/71 |
| ConstipationGastrointestinal disorders | 28/74 | 21/71 |
| PyrexiaGeneral disorders | 25/74 | 17/71 |
| InsomniaPsychiatric disorders | 16/74 | 23/71 |
| RashSkin and subcutaneous tissue disorders | 22/74 | 13/71 |
| Age, Continuous(Years) | Eltrombopag (ELQ) QD | Placebo QD | Total |
|---|---|---|---|
| Mean | 56.7 ± 12.25 | 56.6 ± 11.58 | 56.7 ± 11.88 |
| Sex: Female, Male(Participants) | Eltrombopag (ELQ) QD | Placebo QD | Total |
|---|---|---|---|
| Female | 38 | 31 | 69 |
| Male | 36 | 43 | 79 |
| Race/Ethnicity, Customized(Participants) | Eltrombopag (ELQ) QD | Placebo QD | Total |
|---|---|---|---|
| African American/African Heritage | 1 | 2 | 3 |
| Asian - Central/South Asian Heritage | 0 | 1 | 1 |
| Asian - East Asian Heritage | 26 | 17 | 43 |
| Asian - South East Asian Heritage | 0 | 1 | 1 |
| White - Arabic/North African Heritage | 5 | 3 | 8 |
| White - White/Caucasian/European Heritage | 42 | 50 | 92 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Sep 2013 to primary completion in Mar 2015, 18 months.
Results were first posted in Jun 2016, 1 year 3 months after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Leukemia, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 61. This study's 18 months is below that.
Counting every sponsor, half of 176 studies reached it within 76 months; a quarter within 44 and three quarters within 123.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag